Parallel increase of plasma apoproteins C-II and C-III in type 2 diabetic patients.

BÉLIARD S, NOGUEIRA JP, MARANINCHI M, LAIRON D, NICOLAY A, GIRAL P, PORTUGAL H, VIALETTES B, VALÉRO R.

DIABETIC MEDICINE

WILEY-BLACKWELL PUBLISHING, INC

Año: 2009 vol. 26 p. 736 - 739

0742-3071

Aims To determine plasma levels of apoprotein (apo) C-II and apoproteinC-III in Type 2 diabetic patients and to examine the clinical and biological factors that are associated with elevated apoC concentrations. Methods We measured apoC-II and apoC-III in total plasma and in non-high-density lipoprotein fractions by an immunoturbidimetric assay in 88 Caucasian Type 2 diabetic patients and in 138 healthy control subjects. Results Plasma levels of both apoC-II and apoC-III were increased in Type 2 diabetic patients. The clinical conditions associated with an increase of plasma apoC-II and apoC-III were abdominal obesity, bodymass index, poor glycaemic control and lack of insulin treatment. However, when multivariate analysis was used, plasma apoCs levels correlated with triglyceride levels only. The apoC-III ⁄apoC-II ratio was similar in the Type 2 diabetic and control subjects. Conclusions Our study shows the parallel increase of apoC-II and C-III in Type 2 diabetic patients. This parallel increase is related to hypertriglyceridaemia only.